AMGEN INC
About AMGEN INC
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $36.8B
- Net income
- $7.7B
- Total assets
- $90.6B
- Market cap
- $188.7B
- Gross margin
- 67.2%
- Operating margin
- 24.7%
- Net margin
- 21.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $36.8B
- Cost of revenue
- $12.0B
- Gross profit
- $24.7B
- Operating expenses
- $15.6B
- Operating income
- $9.1B
- Income tax
- $1.3B
- Net income
- $7.7B
- EPS (basic)
- $14.33
- EPS (diluted)
- $14.23
Balance sheet
- Total assets
- $90.6B
- Current assets
- $29.1B
- Total liabilities
- $81.9B
- Current liabilities
- $25.5B
- Shareholders’ equity
- $8.7B
Cash flow
- Operating cash flow
- $10.0B
- Investing cash flow
- -$1.9B
- Financing cash flow
- -$10.9B
- Net cash flow
- -$2.8B
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $188.7B
- P/E ratio
- 24.3
- EPS (diluted)
- $14.23
- Dividend yield
- 2.92%
- Shares outstanding
- 545.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 17, 1983
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $7.7B in FY2025.
- Revenue grew 45% from FY2020 to FY2025.
- Gross margin of 67.2%, net margin 21.0%.
- Trading 11% below its 52-week high.
- Pays a dividend yielding about 2.92% annually.
- Valued at a price-to-earnings (P/E) ratio of 24.3.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review AMGEN INC.
Write a review
News about AMGEN INC
News & sentiment via Polygon.io
